Breaking News
March 19, 2018 - Telediabetes program improves blood sugar control for veterans
March 19, 2018 - Morning Break: House Nixes ‘Right-to-Try’ Bill; Purdue’s PR Makeover; Air in the Brain
March 19, 2018 - Heart researchers develop a new, promising imaging technique for cardiac arrhythmias
March 19, 2018 - Mice study shows how BPA exposure during pregnancy can lead to altered brain development
March 19, 2018 - Breastfeeding mothers who overeat may increase risk of health problems in offspring
March 19, 2018 - New mobile application can detect atrial fibrillation that causes strokes
March 19, 2018 - Study finds low rates of preconception counseling among women of childbearing age with diabetes
March 19, 2018 - ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
March 19, 2018 - D.C. Week: States Plead for Federal $$ in Opioid Fight
March 19, 2018 - Polycystic ovary syndrome – Genetics Home Reference
March 19, 2018 - Reducing co-payments improves patient, physician adherence to guideline-recommended treatment post-MI
March 19, 2018 - Normalizing estrogen levels can benefit female athletes with irregular menstrual periods
March 19, 2018 - Fitness trackers and virtual coaches motivate patients to exercise post cardiac rehab
March 19, 2018 - Atrial fibrillation patients could reduce risk of dementia by taking stroke prevention drugs
March 19, 2018 - Low sperm count more prevalent with other health problems finds study
March 19, 2018 - Male birth control pill taken once a day shows success
March 19, 2018 - AcelRx Announces Receipt of Type A FDA Meeting Minutes and Plans to Resubmit the DSUVIA New Drug Application in Q2 2018
March 19, 2018 - Eye Docs Adopt EHRs Despite Reservations
March 19, 2018 - CRISPR enhances cancer immunotherapy
March 19, 2018 - Study finds first evidence of delayed aging among Americans
March 19, 2018 - Aussies unaware of sun protection rules to prevent skin cancer
March 19, 2018 - Essential oils linked to abnormal breast development in boys
March 19, 2018 - ‘Tummy Tuck’ Relieved Postpartum Back Pain/Incontinence
March 19, 2018 - New biomarkers for neuroblastoma, a type of cancer in children
March 19, 2018 - Hookah Smoking Carries a Poisoning Risk
March 19, 2018 - Do Mood and Anxiety Affect MS Disability?
March 19, 2018 - Mean depth of ultrasonographic penetration greater in autism
March 19, 2018 - Platypus milk may help combat antibiotic resistance
March 19, 2018 - U.S. IDE study of THERMOCOOL SMARTTOUCH SF Catheter completes patient enrollment
March 18, 2018 - E-cigarette use exposes adolescents to potentially cancer-causing chemicals
March 18, 2018 - GOP Senator: Solve Opioid Crisis Through Community, Not Policy
March 18, 2018 - Why is ADHD more common in boys than girls?
March 18, 2018 - Measles alert after two passengers with the disease fly into US
March 18, 2018 - FDA looks to remove nicotine from cigarettes
March 18, 2018 - FDA moves to cut nicotine in cigarettes, helping smokers kick habit
March 18, 2018 - Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis
March 18, 2018 - Surgery Tied to Better Outcomes in Kids with T2D
March 18, 2018 - Scientists use nanotechnology to detect molecular biomarker for osteoarthritis
March 18, 2018 - Research establishes use of chimeric cells as potential therapy for Duchenne muscular dystrophy
March 18, 2018 - Researcher working to develop improved endoscopic probe for colonoscopies
March 18, 2018 - Researchers develop way to sequence entire fetal genome by modifying prenatal testing method
March 18, 2018 - FDA Approves PDUFA Fee Waiver for Gimoti New Drug Application
March 18, 2018 - P2Y12 Tx Subsidy Yields Positive Response from Docs, Patients
March 18, 2018 - Are Proteins in Formula Linked to Type 1 Diabetes?
March 18, 2018 - Exercise does not seem to increase bone marrow edema in healthy people
March 18, 2018 - Researchers delineate architecture of nuclear pore complex in yeast cells
March 18, 2018 - ‘It’s Just Ghetto-izing People’: What We Heard This Week
March 18, 2018 - Alzheimer’s disease: Neuronal loss very limited
March 18, 2018 - Study reveals impact of intense, changing work schedules experienced by medical interns
March 18, 2018 - Jobs That Keep the Mind Sharp … Even Into Retirement
March 18, 2018 - Facial Scarring Improved with Botulinum Toxin
March 18, 2018 - Data detectives shift suspicions in Alzheimer’s to inside villain
March 18, 2018 - Shorter Preventive TB Tx Effective for HIV+ Patients
March 18, 2018 - New technique for identifying alcoholism puts treatment options at patients’ and providers’ fingertips
March 18, 2018 - Researchers uncover four microRNAs as potential biomarkers for atrial fibrillation
March 18, 2018 - IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
March 18, 2018 - OncoBreak: Learning from Silence; ‘Rigged’ Drug System; NCCN Guidelines Questioned
March 18, 2018 - The coffee cannabis connection
March 18, 2018 - Novel centrifugal-flow pump for heart failure patients provides improved long-term outcomes
March 18, 2018 - U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
March 18, 2018 - Cath Lab Recap: iFR vs FFR $$; Ridaforolimus-Eluting Stent
March 18, 2018 - Tree care workers need better training to handle dangers on the job, study finds
March 18, 2018 - Dementia patients do not undergo diagnostic evaluation at onset of disease, study finds
March 18, 2018 - Transplanting enhanced interneurons restores brain rhythms in mouse model of Alzheimer’s
March 18, 2018 - Gene Therapy Flops for Critical Limb Ischemia
March 17, 2018 - Study spotlights risks in anesthesiologist handoffs
March 17, 2018 - Verb fluency test may be useful tool for differential diagnosis of cognitive failure
March 17, 2018 - Health Tip: Suggestions to Improve Your Cholesterol
March 17, 2018 - Fructans Suspect in Non-Celiac Gluten Sensitivity
March 17, 2018 - Aspirin therapy appears safe before thyroid surgery
March 17, 2018 - Minimally invasive surgical device may one day provide lasting heart repair
March 17, 2018 - UIH and RaySearch enter into new partnership
March 17, 2018 - Is BMI Too Inexact? | Medpage Today
March 17, 2018 - Sleep apnea study finds male-female differences in cerebral cortex thickness, symptoms
March 17, 2018 - Leicester research could help identify people with asthma of different severities
March 17, 2018 - Biosense Webster enrolls and treats first AF patient in clinical study of new RF balloon catheter
March 17, 2018 - Participants in rogue herpes vaccine research take legal action
March 17, 2018 - Imara Doses First Patient in Phase 2a Clinical Trial of IMR-687 for Sickle Cell Disease
March 17, 2018 - AAP: Prevent Medication Errors by Improving Processes
March 17, 2018 - Severe sleep apnea during REM sleep tied to acute CV events
FDA Approves Apalutamide (Erleada) to Help Curb a Tough-to-Treat Prostate Cancer

FDA Approves Apalutamide (Erleada) to Help Curb a Tough-to-Treat Prostate Cancer

image_pdfDownload PDFimage_print

WEDNESDAY, Feb. 14, 2018 — A new drug that can stall the progression of a particularly hard-to-treat form of prostate cancer has been approved for use by U.S. health officials.

In a recent study, the drug called Erleada (apalutamide) has shown breakthrough effectiveness in keeping prostate cancer from spreading for two years in men whose disease had not yet traveled to other parts of their body.

After the drug was granted Priority Review by the U.S. Food and Drug Administration, the agency announced Wednesday that it had approved Erleada “for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy.”

A second, already approved drug, Xtandi (enzalutamide), has also shown similar effectiveness against these types of prostate cancer cases.

Dr. Matthew Smith was primary researcher of the Erleada trial that helped lead to the new approval. His team published its results Feb. 8 in the New England Journal of Medicine.

Smith explained that men newly diagnosed with prostate cancer that hasn’t spread are first treated with androgen-deprivation therapy — a medication that robs the tumor of the testosterone that helps fuel its growth.

This strategy “always works, and [then] it almost always stops working,” said Smith, who directs the genitourinary malignancies program at Massachusetts General Hospital in Boston.

“And when it stops working, that’s what we call castration-resistant prostate cancer,” he explained.

Until now, there have been no approved treatments for prostate cancer at that stage, Smith said. The men are simply put under observation until their cancer migrates, at which point treatment resumes.

Tens of thousands of men in the United States are estimated to be in this situation and they have a very poor prognosis, particularly if their levels of prostate-specific antigen (PSA) are rapidly rising, Smith said. PSA is a protein produced by the prostate gland; a sudden elevation of PSA levels has been linked to increased prostate cancer risk.

“There’s an unmet need there,” Smith said. “Their expected survival is similar to that of men with newly diagnosed prostate cancer that has already spread to bone.”

Both Erleada and Xtandi battle prostate cancer by binding to the androgen receptor on tumor cells, blocking its activation by testosterone and other male hormones, explained Dr. Oliver Sartor, medical director of the Tulane Cancer Center in New Orleans. He co-wrote a commentary accompanying the apalutamide trial.

“Both the drugs are incredibly similar to one another,” Sartor said. “If you look at the chemical structure, they’re extremely close to one another. Mechanistically, they operate the same way.”

In the Erleada trial, Smith’s group tested the pill against a placebo.

The result: Erleada extended progression-free survival by about two years over a placebo, researchers found — 40.5 months versus 16.2 months. That means patients continued to live their lives without the disease progressing.

Men taking Erleada had a 72 percent lower risk of invasive cancer or death, based on results from more than 1,200 patients at 322 sites in 26 countries, the study found.

“It was a very big effect,” Smith said.

The FDA said that, in a first for cancer drugs, it based its approval of Erleada not on overall survival results, but on how long patients survived without their cancer spreading.

For his part, Smith said he expects Erleada to become the standard of care for men with this form of prostate cancer.

But other experts think Xtandi could steal the new drug’s thunder.

Dr. Alexander Kutikov, chief of urologic oncology with Fox Chase Cancer Center in Philadelphia, noted that Xtandi demonstrated similar results in studies, and it’s already in use as a prostate cancer therapy.

“I suspect barriers to its use, at least initially, will be much lower than to that of apalutamide [Erleada],” he said.

Sartor agreed. “I think [Erleada] will become a standard of care. I hesitate to think it will be the standard of care,” he said.

And he noted that both drugs come with significant side effects — most commonly rash and increased risk of fracture — and men not suffering any symptoms might not want to take the risk of drug-related adverse events.

For example, rash occurred in almost 24 percent of men taking Erleada versus 5.5 percent in the placebo group. And fractures occurred in close to 12 percent of Erleada users, versus 6.5 percent in the placebo group. However, only about 10 percent of men taking the cancer drug dropped out due to side effects, compared with 7 percent and 8 percent of the placebo groups.

The Erleada trial was paid for by Johnson & Johnson.

More information

For more on prostate cancer, visit the U.S. National Cancer Institute.

© 2018 HealthDay. All rights reserved.

Posted: February 2018

Tagged with:

About author

Related Articles